Some things will always remain unfettered. Like sunshine and air, like suffering and joy, like sharing and caring. Some things will never recognize the confines of space and time. Like human endeavour and enterprise, like the desire to touch life. At Morepen, we are taking our expertise and experience in Wellness to new countries and new people with an increasing focus on global exports. And in doing so, our spirit of caring is crossing boundaries.
Highlights Q4 FY 2018-19
Total Revenue (Standalone) up by 31 percent at Rs. 207.10 crore and Consolidated Total Revenue up by 28 percent at Rs. 219.74 crore registering a good growth in all business segments.
Standalone Net Profit (PAT) is up by 125 percent to... (more)
Highlights Q1 FY 2018-19 (Consolidated)
Net Sales Revenue up by 26 percent at Rs. 161.81 crore backed by improved sales revenue from Home Diagnostics, Formulations and OTC Businesses.
Domestic sales up by 71 percent at Rs. 108.20 crore. EBIDTA rises by 10.4 perc... (more)
Key Highlights
Baddi facility in Himachal Pradesh gets USFDA approval for cholesterol reducing bulk drug “Atorvastatin”.
Masulkhana facility, also in Himachal Pradesh, gets USFDA approval for an anti-asthma bulk drug “Montelukast Sodium”.
Both t... (more)
Highlights 12M FY 2017-18 (Consolidated)
Net profit rises by 25 per cent at Rs. 29.59 Crore.
Net Sales Revenue up by 1.9 per cent at Rs. 598 crore.
Domestic sales up by 21.3 per cent at Rs. 414 crore.
The overall Home Diagnostic category grows ... (more)
Highlights Q3 FY 2017-18
107% increase in Net profit at Rs. 9.67 crore.
Cash profits increase by 32%
EBIDTA growth by 18%
Net Sales Revenue marginally up by 1.9% at Rs. 140 crore.
Domestic Sales are up by 25 per cent at Rs. 103 crore.... (more)
The United States Food and Drug Administration (USFDA) has cleared Montelukast Sodium, a bulk drug / API manufactured by Morepen Laboratories Ltd., for sale in the US market. This gives Morepen an entry into the Rs. 2000 crore (Approx. $ 300 million) US market for Montelukast. The first commercial ... (more)
Highlights Q2 FY 2017-18
Net profit rises by 24 per cent at Rs. 10.37 Crore.
Net Sales Revenue declines marginally by 3 per cent at Rs. 136.43 crore.
Domestic Sales are up by 34.4 per cent at Rs. 101.91 crore.
Exports turnover stood at Rs. 34.5... (more)
Morepen Laboratories Ltd. has entered into a tie-up with Vésale Pharma International of Belgium to strengthen its position in the Rs. 1000 crore Probiotics market in India. An agreement to this effect between the two pharma biggies was officially signed in the august presence of the King and... (more)
Highlights Q4 FY 2016-17
Net profit rises by 179 per cent at Rs. 7.73 Crore.
Net Sales Revenue up by 17.4 per cent at Rs. 141 crore.
Exports turnover up by 29 per cent at Rs. 73 crore.
Loratadine records highest growth amongst bulk drugs in the... (more)
The pharma-cum-healthcare major, Morepen Laboratories Ltd., has reported a yet another growth-filled quarter by registering a 23 per cent rise in its net sales in the third quarter (Q3) of fiscal 2016-17. The net sales increased to Rs. 134.05 crore in Q3 FY 2016-17 compared to Rs. 10... (more)
